Online inquiry

IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6831MR)

This product GTTS-WQ6831MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL3RA gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3563
UniProt ID P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6831MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4607MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ3084MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA APG-101
GTTS-WQ2441MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ4691MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ10871MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ9823MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ15961MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ14922MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Shigamabs®
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW